Table 2.
Allele and genotype frequencies in PD patients and controls.
| Gene SNP | Group | MA n (freq) | pallelic | Genotype | pgenotype | ORa | pOR | ||
|---|---|---|---|---|---|---|---|---|---|
|
LRRK2 rs1491942 |
PD | 155 (0.67) | 0.003 | CC | CG | GG | 0.01 |
1.71 (1.22–2.40) |
0.002 |
| 14 (0.12) | 53 (0.45) | 51 (0.43) | |||||||
| CNT | 205 (0.53) | 44 (0.22) | 93 (0.48) | 56 (0.29) | |||||
|
MTHFR rs1801133 |
PD | 137 (0.58) | 0.01 | CC | CT | TT | 0.041 |
1.54 (1.11–2.15) |
0.01 |
| 23 (0.19) | 53 (0.45) | 42 (0.36) | |||||||
| CNT | 183 (0.47) | 55 (0.29) | 93 (0.48) | 45 (0.23) | |||||
|
USP24 rs13312 |
PD | 20 (0.09) | 0.99 | CC | CG | GG | 0.99 |
0.91 (0.49–1.71) |
0.79 |
| 96 (0.83) | 18 (0.16) | 1 (0.01) | |||||||
| CNT | 24 (0.10) | 104 (0.83) | 20 (0.16) | 2 (0.02) | |||||
|
PARK7 rs3766606 |
PD | 20 (0.03) | 0.67 | GG | GT | TT | 0.83 |
0.87 (0.49–1.54) |
0.64 |
| 99 (0.84) | 18 (0.15) | 1 (0.09) | |||||||
| CNT | 37 (0.06) | 157 (0.81) | 35 (0.18) | 1 (0.05) | |||||
|
NUCKS1 rs823128 |
PD | 32 (0.13) | 0.90 | AA | AG | GG | 0.56 |
0.94 (0.58–1.50) |
0.80 |
| 90 (0.76) | 24 (0.20) | 4 (0.04) | |||||||
| CNT | 55 (0.14) | 142 (0.74) | 47 (0.24) | 4 (0.02) | |||||
|
SLC41A1 rs823156 |
PD | 51 (0.22) | 0.29 | AA | AG | GG | 0.09 |
0.79 (0.54–1.17) |
0.25 |
| 76 (0.64) | 33 (0.28) | 9 (0.08) | |||||||
| CNT | 99 (0.26) | 105 (0.54) | 77 (0.40) | 11 (0.06) | |||||
|
GSK3B rs334558 |
PD | 85 (0.36) | 0.43 | AA | GA | GG | 0.44 |
1.14 (0.81–1.61) |
0.42 |
| 51 (0.43) | 49 (0.41) | 18 (0.15) | |||||||
| CNT | 127 (0.33) | 86 (0.45) | 87 (0.47) | 20 (0.10) | |||||
|
DRD3 rs6280 |
PD | 99 (0.42) | 0.16 | TT | TC | CC | 0.23 |
0.75 (0.54–1.05) |
0.10 |
| 42 (0.36) | 52 (0.44) | 24 (0.20) | |||||||
| CNT | 188 (0.49) | 51 (0.26) | 96 (0.49) | 46 (0.24) | |||||
|
FAM47E/ SCARB2 rs6812193 |
PD | 49 (0.21) | 0.4 | CC | CT | TT | 0.31 |
1.2 (0.80–1.82) |
0.37 |
| 78 (0.66) | 31 (0.27) | 9 (0.08) | |||||||
| CNT | 69 (0.18) | 131 (0.68) | 55 (0.26) | 7 (0.04) | |||||
|
SNCA rs356219 |
PD | 90 (0.38) | 0.21 | GG | AG | AA | 0.29 |
0.79 (0.57–1.11) |
0.18 |
| 47 (0.40) | 52 (0.44) | 19 (0.16) | |||||||
| CNT | 168 (0.44) | 60 (0.31) | 98 (0.51) | 35 (0.18) | |||||
|
PARK2 rs1801474 |
PD | 36 (0.15) | 0.48 | CC | CT | TT | 0.58 |
1.18 (0.74–1.87) |
0.48 |
| 85 (0.72) | 30 (0.25) | 3 (0.03) | |||||||
| CNT | 51 (0.13) | 148 (0.77) | 39 (0.20) | 6 (0.03) | |||||
|
PARK2 rs1801582 |
PD | 27 (0.11) | 0.73 | CC | CG | GG | 0.94 |
1.09 (0.65–1.83) |
0.77 |
| 93 (0.78) | 23 (0.19) | 2 (0.017) | |||||||
| CNT | 60 (0.16) | 155 (0.80) | 35 (0.18) | 3 (0.015) | |||||
|
ANKK1 rs1800497 |
PD | 103 (0.44) | 0.62 | CC | CT | TT | 0.63 |
0.91 (0.65–1.26) |
0.58 |
| 41 (0.35) | 51 (0.43) | 26 (0.22) | |||||||
| CNT | 177 (0.46) | 58 (0.30) | 93 (0.48) | 42 (0.22) | |||||
|
LRRK2 rs1994090 |
PD | 32 (0.14) | 0.62 | TT | TG | GG | 0.58 |
1.16 (0.71–1.88) |
0.55 |
| 87 (0.74) | 30 (0.25) | 1 (0.008) | |||||||
| CNT | 46 (0.12) | 150 (0.78) | 40 (0.21) | 3 (0.015) | |||||
|
MAPT rs242562 |
PD | 76 (0.32) | 0.12 | AA | AG | GG | 0.29 |
0.75 (0.53–1.06) |
0.11 |
| 51 (0.43) | 57 (0.48) | 10 (0.08) | |||||||
| CNT | 149 (0.39) | 68 (0.35) | 101 (0.52) | 24 (0.12) | |||||
|
RAIL/ SREBF1 rs11868035 |
PD | 112 (0.47) | 0.16 | AA | AG | GG | 0.39 |
1.29 (0.92–1.81) |
0.13 |
| 36 (0.31) | 52 (0.44) | 30 (0.25) | |||||||
| CNT | 160 (0.41) | 72 (0.37) | 82 (0.43) | 39 (0.20) | |||||
MA minor allele frequency, PD Parkinson disease patients, CNT controls.
pallelic p value allelic comparison, pgenotype p value genotype comparison, pOR p value OR
aOR (CI 95%) additive model adjusted by sex, age, and ancestry.